BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
ClinicalTrials.gov ID: NCT06204835
What this study is testing
What is RD-Cy7 fluorophore?
RD-Cy7 fluorophore is an investigational medicine, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients who have been diagnosed with hepatocellular carcinoma.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A.
- ITGA6 was validated highly expressed preoperatively.
- Aged 18 to 80, and the expected lifetime is longer than 6 months.
You likely can't join if
- Allergic to Cy7.
- Enrolled in other trials in the past 3 months.
- Another malignant tumor was found.
- Undesirable function of heart, lung, kidney, or any other organs.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
See the full eligibility criteria
- Patients who have been diagnosed with hepatocellular carcinoma.
- Planned to receive hepatectomy.
- Liver function Child-Pugh A.
- ITGA6 was validated highly expressed preoperatively.
- Aged 18 to 80, and the expected lifetime is longer than 6 months.
- Approved to sign the informed consent.
- Allergic to Cy7.
- Enrolled in other trials in the past 3 months.
- Another malignant tumor was found.
- Undesirable function of heart, lung, kidney, or any other organs.
- Unable to tolerate a hepatectomy.
- The researchers considered inappropriate to be included.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
- Luzhou, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China; Luzhou, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.